LX 2931

Drug Profile

LX 2931

Alternative Names: LX 3305; LX2931

Latest Information Update: 20 May 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Lexicon Pharmaceuticals
  • Developer CureDuchenne Ventures; Lexicon Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Immunosuppressants; Lymphocyte inhibitors; Sphingosine 1 phosphate lyase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Rheumatoid arthritis

Highest Development Phases

  • Phase II Rheumatoid arthritis
  • Preclinical Duchenne muscular dystrophy

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 20 May 2016 Phase-II development is ongoing in USA, Czech Republic, Bulgaria, Hungary, Poland and Serbia
  • 26 Sep 2013 Preclinical trials in Duchenne muscular dystrophy in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top